Strategic partnerships Zephyr AI actively partners with health systems, health plans, and biotech pioneers to drive improvements in quality, outcomes, and costs, presenting opportunities to collaborate on payer-driven precision medicine initiatives and joint pilot programs.

Oncology focus With a clear emphasis on oncology and cardiometabolic diseases, Zephyr AI aligns with cancer centers and pharma/biotech sponsors seeking AI-enabled biomarker insights, targeted therapy selection, and drug response monitoring.

Series A momentum Recent $111M Series A funding from high-profile investors signals strong growth potential and validation, suggesting upsell and expansion opportunities with existing investors, as well as credibility for new enterprise deals.

Enterprise tech stack Utilizing cloud and enterprise tools such as Microsoft Azure, Adobe Experience Cloud, DocuSign, and Google Workspace indicates readiness for scalable deployments, secure data sharing, and integration with large health networks; target IT and security leaders for platform integrations.

Leadership signals New CFO appointment and prior C-suite hires imply evolving governance and financial discipline, opening doors for procurement conversations, long-term contract pricing, and visibility into budgeting cycles within health systems and biopharma partners.